Vincerx Pharma, Inc. (VINC)
OTCMKTS · Delayed Price · Currency is USD
0.0127
0.00 (0.00%)
At close: Aug 14, 2026
Vincerx Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 4.44 | 4.99 | 12.78 | 11.66 | 111.46 | 61.79 |
Short-Term Investments | - | - | - | 40.8 | - | - |
Cash & Short-Term Investments | 4.44 | 4.99 | 12.78 | 52.46 | 111.46 | 61.79 |
Cash Growth | -13.17% | -60.98% | -75.63% | -52.93% | 80.38% | - |
Other Receivables | - | 1.04 | 1.04 | 1.37 | - | - |
Receivables | - | 1.04 | 1.04 | 1.37 | - | - |
Prepaid Expenses | 0.12 | 0.09 | 0.05 | 0.13 | 0.18 | 1.1 |
Restricted Cash | 0.08 | 0.08 | 0.07 | 0.07 | 0.11 | - |
Other Current Assets | 0.04 | 0.21 | 0.78 | 1.93 | 0.1 | 0.21 |
Total Current Assets | 4.69 | 6.41 | 14.73 | 55.96 | 111.84 | 63.11 |
Property, Plant & Equipment | - | - | 2.33 | 3.24 | 4.18 | - |
Other Long-Term Assets | - | 1.6 | 1.16 | 0.08 | 1.65 | 0.08 |
Total Assets | 4.69 | 8.01 | 18.22 | 59.29 | 117.68 | 63.19 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 2.27 | 2.03 | 2.5 | 4.07 | 2.02 | 0.49 |
Accrued Expenses | 0.35 | 3.24 | 1.76 | 3.92 | 4.72 | 5 |
Current Portion of Leases | - | - | 1.16 | 1.02 | 0.74 | - |
Other Current Liabilities | - | 0.01 | 0.19 | 0.14 | 6.45 | 32.32 |
Total Current Liabilities | 2.62 | 5.28 | 5.61 | 9.16 | 13.92 | 37.81 |
Long-Term Leases | - | - | 1.34 | 2.41 | 3.44 | - |
Other Long-Term Liabilities | - | - | 0.05 | 0.05 | - | - |
Total Liabilities | 2.62 | 5.28 | 7 | 11.62 | 17.36 | 37.81 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | - | - | 0 | 0 | 0 |
Additional Paid-In Capital | 196.08 | 191.79 | 170.33 | 166.65 | 156.31 | 42.04 |
Retained Earnings | -194.19 | -189.19 | -159.11 | -118.96 | -55.97 | -16.67 |
Comprehensive Income & Other | 0.17 | 0.12 | 0.01 | -0.03 | -0.02 | - |
Shareholders' Equity | 2.07 | 2.72 | 11.22 | 47.67 | 100.32 | 25.38 |
Total Liabilities & Equity | 4.69 | 8.01 | 18.22 | 59.29 | 117.68 | 63.19 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | - | - | 2.5 | 3.44 | 4.17 | - |
Net Cash (Debt) | 4.44 | 4.99 | 10.28 | 49.02 | 107.29 | 61.79 |
Net Cash Growth | 53.48% | -51.49% | -79.03% | -54.31% | 73.62% | - |
Net Cash Per Share | 1.76 | 2.63 | 9.65 | 46.62 | 124.92 | 235.31 |
Filing Date Shares Outstanding | 5.23 | 5.23 | 1.07 | 1.06 | 1.05 | 0.7 |
Total Common Shares Outstanding | 5.23 | 2.24 | 1.07 | 1.06 | 1.05 | 0.7 |
Working Capital | 2.07 | 1.13 | 9.13 | 46.81 | 97.92 | 25.3 |
Book Value Per Share | 0.39 | 1.22 | 10.48 | 44.88 | 95.28 | 36.30 |
Tangible Book Value | 2.07 | 2.72 | 11.22 | 47.67 | 100.32 | 25.38 |
Tangible Book Value Per Share | 0.39 | 1.22 | 10.48 | 44.88 | 95.28 | 36.30 |
Machinery | - | - | 0.26 | 0.26 | 0.26 | - |